ClinicalTrials.gg

Program

MHB009C

A development code. Also written as “MHB009C for Injection”.

Its studies are led by Minghui Pharmaceutical.

Furthest: phase 2, since Dec 22, 20251 company-led study, 1 open or runningNext primary completion: Feb 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Minghui Pharmaceutical11 open or runningphase 2since Dec 22, 2025Dec 22, 2025Feb 2028phase 2 · NCT07326488

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 22, 2025First study: phase 2 study in Advanced Malignant Solid TumorFirst studyNCT07326488 · 200 planned · China

Ahead

  1. Feb 2028Primary completion: phase 2 study in Advanced Malignant Solid TumorNCT07326488

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07326488Advanced Malignant Solid Tumor · China2RecruitingFeb 2028200

How it is read

Names in the registry

  • “MHB009C for Injection”, 1 entry

Codes read as this program: MHB009C.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.